DYN Stock Analysis: Buy, Sell, or Hold?
DYN - Dyne Therapeutics, Inc. Common Stock
$23.07
1.28 (5.87%)
▲
5d:
+11.94%
30d:
+33.82%
90d:
+27.46%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 27, 2026
23d
Get Alerted When DYN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: DYN is 10.5% above its trading range ($20.87). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: DYN is 10.5% above its trading range ($20.87). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: DYN is currently trading at $23.07, which is considered extended relative to its 30-day fair value range of $17.59 to $20.87.
Technical Outlook: Technically, DYN is in a uptrend. The price is approaching resistance at $23.09. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: DYN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $38.25 (+65.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DYN is in a uptrend. The price is approaching resistance at $23.09. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: DYN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $38.25 (+65.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.59 -
$20.87
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
DYN is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+10.5% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 65.8% below Wall St target ($38.25)
Trading Range Analysis
30-Day Trading Range
$17.59 -
$20.87
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$19.14
Resistance Level
$23.09
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.71
Wall Street Target
$38.25
(+65.8%)
Share & Embed Analysis
Last updated: July 02, 2026 11:40 PM ET
Data refreshes hourly during market hours. Next update: 12:40 AM
Data refreshes hourly during market hours. Next update: 12:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason P Rhodes
SELL
287956 shares
2026-04-22
Jason P Rhodes
SELL
274297 shares
2026-04-21
Jason P Rhodes
SELL
272049 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
Advanced DYN Option Strategies
Professional options setups generated by AI based on today's DYN price and gamma walls.